Citations

Clear

16280 citation(s) found for "Yu, David".

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Thakolwiboon, Smathorn , Redenbaugh, Vyanka , Chen, Bo , Hewitt, S., Shah, Shailee , Lotan, Itay , Levy, Michael , Forcadela, Mirasol , Huda, Saif , Pique, Julie , Marignier, Romain , Audoin, Bertrand , Poullin, Pascale , Champsas, Dimitrios , Choi, David, Danesh‐Meyer, Helen V. , Vasileiou, Eleni S. , Sotirchos, Elias S. , Davis, James , Wilf‐Yarkoni, Adi , Bonelli, Laura , Arnold, Anthony C. , Motte, Marine Boudot de la , Deschamps, Romain , Jitprapaikulsan, Jiraporn , Moss, Heather E. , Navarro, Sylvia E. Villarreal , Mao‐Draayer, Yang , Mishra, Murli , Tisavipat, Nanthaya , Tajfirouz, Deena , Tillema, Jan-Mendelt , López‐Chiriboga, A. Sebastian , Palace, Jacqueline , Chen, John J. , Boutiere, Clemence , Audoin, Bertrand , Champsas, Dimitrios , Vasileiou, Eleni , Sotirchos, Elias S , Henderson, Amanda D , Wilf-Yarkoni, Adi , Stiebel-Kalish, Hadas , Maillart, Elisabeth , Bonelli, Laura , Deschamps, Romain , Jitprapaikulsan, Jiraporn , Moss, Heather E , Villarreal Navarro, Sylvia E , Mao-Draayer, Yang , Mishra, Murli , Vorasoot, Nisa , Cacciaguerra, Laura , Tisavipat, Nanthaya , Tajfirouz, Deena , Tillema, Jan‐Mendelt , Lopez-Chiriboga, A Sebastian , Palace, Jacqueline , Hacohen, Yael , Pittock, S J , Flanagan, E P , Chen, John J , Levy, Michael , Shah, Shailee , Lotan, Itay , Thakolwiboon, Smathorn , Hewitt, Sage, Henderson, Amanda D. , Stiebel‐Kalish, Hadas , Vorasoot, Nisa , Cacciaguerra, Laura , Hacohen, Yael , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Neurology | August 29, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000213903 | PMID 40882166 Get It

Inter-rater Agreement of Richmond Agitation Sedation Scale Assessments in Adult Patients Receiving Mechanical Ventilation in the ICU: A Cross-Sectional Study
Fuchita, Mikita , Pattee, Jack , Le, Dung , To, Teresa , Mucharraz, Carlos , Knippa, Sara, Keyworth, Alexis, Blaine, Caitlin, Le, David, To, Tien, Lindroth, Heidi

Mayo Clinic

Critical Care Explorations | August 28, 2025 | Volume: 7 | Issue: 9 | Pages: e1302

10.1097/cce.0000000000001302 | PMID 40875505 Get It

IMPORTANCE: Accurate and reliable sedation assessment is crucial to improving patient outcomes in the ICU. OBJECTIVE: To evaluate the inter-rater agreement and reliability of Richmond Agitation Sedation Scale (RASS) assessments between bedside nurses and trained investigators in patients receiving mechanical ventilation in the ICU. DESIGN, SETTING, AND PARTICIPANTS: An assessor triad, comprising an ICU nurse providing direct patient care and two trained investigators, simultaneously performed RASS assessments during 79 encounters with 62 unique patients receiving mechanical ventilation at two ICUs at a tertiary care academic hospital in Colorado. A total of 58 nurses participated in the study. MAIN OUTCOMES AND MEASURES: The inter-rater reliability of RASS assessments was evaluated with the intraclass correlation coefficient (ICC) and weighted kappa (κ), and inter-rater agreement was evaluated with percentage agreement and Bland-Altman analysis. RESULTS: Acute respiratory failure (55%) and altered mental status (21%) were the most common reasons for mechanical ventilation. Most patients were receiving one (interquartile range, 0.5–2) continuous sedative during the assessment. The inter-rater reliability of RASS assessments between the nurses and investigators (ICC, 0.728–0.779; weighted κ, 0.62–0.63) was lower than between the two investigators (ICC, 0.891; weighted κ, 0.80). The assessor triad agreed on the same RASS values in only 35% of observations. The average differences in RASS were greater between the investigators and nurses, ranging from –0.658 to –0.544, compared with 0.114 between the two investigators. Compared with the mean of the two investigators, RASS values recorded by nurses were more likely to be higher (52% of observations), indicating a lighter sedation level. In 16% of observations, at least one assessor commented on uncertainty or ambiguity with the RASS. CONCLUSIONS AND RELEVANCE: The inter-rater reliability of RASS assessments was high. However, we observed variations in the degree of agreement by assessor category. Further studies are necessary to explore how factors such as assessor characteristics, ICU environment, and patient conditions influence the inter-rater agreement of the RASS in contemporary ICU practices.
Left atrial appendage occlusion in patients with end-stage renal disease: an individual patient-level meta-analysis
Rodriguez, Juan F. , Vemulapalli, Hema Srikanth , Akın, İbrahim , Areiza, Luis A , Rocca, Domenico G. Della , Eitel, Ingo , Fink, Thomas , Genovesi, Simonetta , Kefer, Joëlle , Prajapati, Poojan , Srivathsan, Komandoor , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Della Rocca, Domenico G , Zweiker, David , Prajapati, Poojan , Srivathsan, Komandoor

Mayo Clinic

Europace | August 28, 2025 | Volume: 27 | Issue: 10 | Pages: No page available

10.1093/europace/euaf198 | PMID 40879386 Get It

Abstract Aims Patients with end-stage renal disease (ESRD) and atrial fibrillation present a challenge for thromboembolic prevention, given their elevated risks of both thromboembolism and bleeding. Anticoagulants carry a higher bleeding risk in this population without clear evidence of thromboembolic benefit. This study aims to define the role of left atrial appendage occlusion (LAAO) as a preventive strategy for patients with ESRD. Methods and results A systematic literature review was conducted to identify studies reporting outcomes in patients with ESRD who underwent LAAO. Meta-analyses of aggregate and individual patient data were performed to evaluate acute and long-term outcomes and compare them with those of patients without ESRD. Seventeen studies reporting data from 24 127 patients, including 1047 with ESRD, were included. Procedural complications were more common in patients with ESRD (RR 2.23; P = 0.02), with a pooled rate of 4% (95% CI, 1–9%). There was no significant difference in thromboembolic event rates during follow-up between the groups (IRR 1.44; P = 0.16), but major bleeding incidence was higher among patients with ESRD (IRR 1.84; P < 0.01). Individual patient-level data from seven studies comprising 4745 patients (268 with ESRD) were obtained and analysed. Similarly, there was no significant association between ESRD and stroke/TIA incidence (HR, 1.22; 95% CI, 0.66–2.26), but major bleeding was higher on patients with ESRD (HR, 1.65; 95% CI, 1.01–2.69). Conclusion LAAO represents a feasible option for thromboembolic prevention in patients with ESRD, although these patients have an increased risk of complications and bleeding.
Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Grossberg, Jonathan A , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Mascitelli, Justin, Fragata, Isabel , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter , Maier, Ilko , Jabbour, Pascal , Samaniego, Edgar A , Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Fragata, Isabel , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Kasab, Sami Al , Goyal, Nitin , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Osbun, Joshua W , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Chen, Huanwen

Mayo Clinic

European Stroke Journal | August 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/23969873251364973 | PMID 40873294 Get It

Introduction: Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods: This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results: 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts ( p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions: Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension
Lópes, Renato D. , Cargill, Victoria A., Cowie, Martín , Cushman, William C. , Elkind, Mitchell S.V. , Epstein, Shilpi, Garg, Pushkal, Gersh, Bernard J. , Giakoumis, M. , Guo, Weinong, Kirtane, Ajay J. , Lefkowitz, Marty , Lesogor, Anastasia, Ohman, E. Magnus , Pagidipati, Neha J. , Reboussin, David M. , Roessig, Lothar, Roger, Véronique L. , Sánchez, Eduardo , Stockbridge, Norman, Weber, Michael A. , Whelton, Seamus P. , Lopes, Renato D , Cowie, Martin R , Cushman, William C , Elkind, Mitchell S V , Gersh, Bernard J , Giakoumis, Michail , Green, Jennifer B , Kirtane, Ajay J , Lefkowitz, Martin P , Mensah, George A. , O'Donoghue, Michelle L , Ohman, E Magnus , Pagidipati, Neha J , Roger, Veronique L , Sanchez, Eduardo J , Stockbridge, Norman , Touyz, Rhian M , Van Spall, Harriette G C , Weber, Michael A , Whelton, Seamus P , Hernandez, Adrian , Yancy, Clyde W. , Granger, Christopher B , Krychtiuk, Konstantin A , Chen, Roland K. , Ohman, E. Magnus, Touyz, Rhian M. , Spall, Harriette G.C. Van , Hernandez, Adrian F. , Granger, Christopher B.

Mayo Clinic

Hypertension | August 26, 2025 | Volume: 82 | Issue: 10 | Pages: 1599-1611

10.1161/hypertensionaha.125.24992 | PMID 40874957 Get It

Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox—blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.
Mild Behavioral Impairment: A Population-Based Study
Vassilaki, Maria , Syrjanen, Jeremy A. , Graff‐Radford, Jonathan , Fields, Julie A. , Knopman, David S., Petersen, Ronald , Geda, Yonas E., Krell-Roesch, Janina, Krell‐Roesch, Janina , Vemuri, Prashanthi , Kremers, Walter K. , Jack, Clifford R. , Lyketsos, Constantine G.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | August 26, 2025 | Volume: 38 | Issue: 2 | Pages: 134-143

10.1176/appi.neuropsych.20240155 | PMID 41837745 Get It

Depression and Cognitive Outcomes: Linking the Mayo Clinic Study of Aging and Rochester Epidemiology Project
Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Knopman, David S., Petersen, Ronald , Vassilaki, Maria , Krell-Roesch, Janina, Kremers, Walter K , Krell‐Roesch, Janina , Geda, Yonas E.

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | August 26, 2025 | Volume: 38 | Issue: 1 | Pages: 45-52

10.1176/appi.neuropsych.20240094 | PMID 41572474 Get It

Digital Health in Stroke Neurology: Current State and Future Directions
Sohutskay, David O , Tvrdá, Lucie , Keser, Zafer , Keser, Zafer

Mayo Clinic

Stroke | August 25, 2025 | Volume: 56 | Issue: 9 | Pages: No page available

10.1161/strokeaha.124.049469 | PMID 40854037 Get It

Outcomes Associated With SGLT2 Inhibitor Use Following Acute Myocardial Infarction Without Heart Failure: A Propensity-Matched Study
Issa, Rochell , Calcagno, Tess , Canova, Tyler , Issa, Ryan, Menon, Venu , Griffin, Brian P. , Kwon, Deborah , Wang, Tom Kai Ming , Wang, Tom Kai Ming , Kaelber, David C. , Tang, W.H. Wilson

Mayo Clinic

Angiology | August 25, 2025 | Volume: 77 | Issue: 6 | Pages: 704-713

10.1177/00033197251365016 | PMID 40852947 Get It

This retrospective propensity-matched cohort study assessed the association between sodium-glucose co-transporter-2 inhibitor (SGLT2i) use and cardiovascular outcomes in patients with acute myocardial infarction (AMI) without a history of heart failure. Using the TriNetX U.S. Collaborative Network, we identified 1440 matched patients (720 SGLT2i+ vs 720 SGLT2i−) with preserved ejection fraction and no prior heart failure. Nearly 90% of patients had diabetes. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of MI, stroke, heart failure, and all-cause mortality. At 1 year, MACE occurred in 17.4% of SGLT2i+ versus 22.0% of SGLT2i− patients (odds ratio [OR] 0.746, 95% CI 0.574-0.969; P = .028), and all-cause mortality occurred in 3.1% versus 7.6%, respectively (OR 0.389, 95% CI 0.234-0.645; P < .001). SGLT2i use was also associated with lower risks of major bleeding. Findings were consistent over long-term follow-up. While the observed associations suggest potential cardioprotective effects of SGLT2i post-MI in patients without heart failure, residual confounding cannot be excluded. The observed reduction in bleeding events is novel and warrants further investigation in prospective studies.